SAMSUNG EPIS HOLDINGS is a holding company established in 2025 that controls two subsidiaries: Samsung Bioepis and Epix Lab. Samsung Bioepis develops and commercializes biosimilars for autoimmune, oncology, ophthalmology, hematology, and bone diseases, with a portfolio including biosimilars of Remicade, Herceptin, Enbrel, Humira, Avastin, Lucentis, Soliris, Eylea, Stelara, Prolia, and Xgeva. The company sells these products globally through partnerships with pharmaceutical companies and direct sales channels in markets including the United States, Europe, Canada, Australia, Brazil, and Japan. Samsung Bioepis is also developing antibody-drug conjugates (ADCs), including a Nectin-4 ADC in clinical trials and an EGFR-HER3 ADC in preclinical stages, in collaboration with Intocell and Phrontline Biopharma. Epix Lab focuses on developing next-generation biotechnology platforms, including peptide-related technologies, for future new drug candidate development and potential technology licensing.

Summarised from the company's own disclosures, fiscal year ended May 2026

Industry Biotechnology Homepage samsungepisholdings.com
Sector Healthcare IR page —
Tags
biosimilars, antibody-drug conjugates, oncology, autoimmune diseases, ophthalmology, hematology, bone diseases, biotechnology platforms, peptide technologies, Samsung Bioepis, Epix Lab, Remicade, Herceptin, Enbrel, Humira, Avastin, Lucentis, Soliris, Eylea, Stelara, Prolia, Xgeva, Nectin-4 ADC, EGFR-HER3 ADC, Intocell, Phrontline Biopharma
Press page —

Metrics

Valuation  
Market cap ₩ 8.958T
Market cap (USD) $ 6.593B
P/E 104.86
PEG —
P/BV 1.47
P/S 35.59
P/OCF -86.35
P/FCF -81.38
Dividend yield —
Turnover / mcap —
Returns  
ROE 1.4%
ROI 1.4%
ROIC -0.81%
Profit margin 33.9%
Growth  
Revenue growing —
Profits growing —
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding —
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score -10.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025
Revenue 251.69B
Net profit 85.313B
Free cash flow -110.078B

Filed figures

Figure Dec 2025
Balance sheet detail
Trade receivables (KRW) 382B
Borrowings, current (KRW) 282B
Borrowings, non-current (KRW) 95B
Lease liabilities (KRW) 1.1B
Cash and deposits (KRW) 131B
Intangible assets (KRW) 5.32T
Right-of-use assets (KRW) 1.66B
Net debt (borrowings + leases - cash) (KRW) 247B
Cash flow detail
Operating cash flow (KRW) -104B
Purchases of property, plant and equipment (KRW) -6.33B
Purchases of intangible assets (KRW) -33.7B
Change in receivables (cash effect) (KRW) -59B
Change in inventories (cash effect) (KRW) -13.7B
Change in payables (cash effect) (KRW) -24.7M
Share buybacks (cash effect) (KRW) -20.2B
Interest paid (cash effect) (KRW) -1.67B
Income taxes paid (cash effect) (KRW) -229M
Operating cash flow before change in receivables (KRW) -44.7B
Free cash flow (OCF - PPE - intangibles) (KRW) -144B
Income detail
Total comprehensive income (KRW) 87.8B
Comprehensive income to owners (KRW) 87.8B
Provision for credit losses (KRW) 482M
Reported May 15, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

현금ㆍ현물배당결정(자회사의 주요경영사항) Bull 0 Bear 0 Capital return

Prompts

SAMSUNG EPIS HOLDINGS (ticker 0126Z0), listed in South Korea.

ETFs Holding SAMSUNG EPIS HOLDINGS

ETF Weight in ETF Shares Market value As of
HELX 0.37% 376 $ 104.357K Jun 30, 2026
AVXC 0.07% 1,054 $ 276.482K Nov 16, 2026
RFEM 0.05% 151 $ 39.717K Jul 31, 2026
DFSE 0.04% 839 $ 216.931K Nov 12, 2026
DFEM 0.02% 5,864 $ 1.516M Nov 12, 2026
DFEV 0.01% 1,045 $ 270.194K Nov 12, 2026
DFAX 0.01% 5,382 $ 1.392M Nov 12, 2026
AVEM 0.01% 11,895 $ 3.12M Nov 16, 2026
AVSE 0.01% 42 $ 11.017K Nov 16, 2026
DFAE 0.01% 2,914 $ 753.441K Nov 12, 2026
DEXC 0.00% 49 $ 12.669K Nov 12, 2026
DEHP 0.00% 70 $ 18.099K Nov 12, 2026